Clopidogrel treatment
Phase 3Small molecule
Clopidogrel treatment is one of 12 small molecule programs targeting Scleroderma. It is currently in Phase 3.
2
Indications
2
Total Trials
2
Active Trials
11
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
7 competitors in Scleroderma
#DrugCompanyPhaseTrials
1Lipitor
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Approved
Xylocaine
MMEDRx USA, Inc.
Approved
Rezurock
KKadmon, a Sanofi Company
Approved
Clopidogrel treatment
UUniversity Hospital, Bordeaux
Phase 3
Admsc
UUniversity Hospital, Toulouse
Phase 2
Letairis
GileadPreclinical
Hyperpolarized Xe129
UUniversity of Kansas Medical Center
Preclinical
MMF Immunosuppression
WWondercel Biotech (ShenZhen)
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Clopidogrel treatment. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 3[1]
- Company
- UUniversity Hospital, Bordeaux